2-Aryl-3,6-dialkyl-5-dialkylaminopyrimidin-4-ones as novel CRF-1 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 15, 2003, Pages 2497-2500

  Hodgetts, Kevin J ^a   Yoon, Taeyoung ^a   Huang, Jianhua ^a   Gulianello, Michael ^a   Kieltyka, Andrzej ^a   Primus, Renee ^a   Brodbeck, Robbin ^a   De Lombaert, Stéphane ^a   Doller, Darío ^a  

^a NEUROGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CRF RECEPTOR TYPE 1; DMP 904; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; KETONE DERIVATIVE; NGD 981; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROSOME; PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

EID: 0037633744     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00483-9     Document Type: Article

References (16)

1. For recent reviews, see: (a) Holsboer F. Curr. Opinion Invest. Drugs. 4:2003;46 (b) Kehne J., De Lombaert S. Curr. Drug Targets. 1:2002;467 (c) Lanier M., Williams J.P. Expert Opin. Ther. Patents. 12:2002;1619 (d) Grigoriadis D.E., Haddach M., Ling N., Saunders J. Curr. Med. Chem. 1:2001;63 (e) Gilligan P.J., Robertson D.W., Zaczek R. J. Med. Chem. 43:2000;1641.
2. For recent reviews, see: (a) Holsboer F. Curr. Opinion Invest. Drugs. 4:2003;46 (b) Kehne J., De Lombaert S. Curr. Drug Targets. 1:2002;467 (c) Lanier M., Williams J.P. Expert Opin. Ther. Patents. 12:2002;1619 (d) Grigoriadis D.E., Haddach M., Ling N., Saunders J. Curr. Med. Chem. 1:2001;63 (e) Gilligan P.J., Robertson D.W., Zaczek R. J. Med. Chem. 43:2000;1641.
3. For recent reviews, see: (a) Holsboer F. Curr. Opinion Invest. Drugs. 4:2003;46 (b) Kehne J., De Lombaert S. Curr. Drug Targets. 1:2002;467 (c) Lanier M., Williams J.P. Expert Opin. Ther. Patents. 12:2002;1619 (d) Grigoriadis D.E., Haddach M., Ling N., Saunders J. Curr. Med. Chem. 1:2001;63 (e) Gilligan P.J., Robertson D.W., Zaczek R. J. Med. Chem. 43:2000;1641.
4. For recent reviews, see: (a) Holsboer F. Curr. Opinion Invest. Drugs. 4:2003;46 (b) Kehne J., De Lombaert S. Curr. Drug Targets. 1:2002;467 (c) Lanier M., Williams J.P. Expert Opin. Ther. Patents. 12:2002;1619 (d) Grigoriadis D.E., Haddach M., Ling N., Saunders J. Curr. Med. Chem. 1:2001;63 (e) Gilligan P.J., Robertson D.W., Zaczek R. J. Med. Chem. 43:2000;1641.
5. For recent reviews, see: (a) Holsboer F. Curr. Opinion Invest. Drugs. 4:2003;46 (b) Kehne J., De Lombaert S. Curr. Drug Targets. 1:2002;467 (c) Lanier M., Williams J.P. Expert Opin. Ther. Patents. 12:2002;1619 (d) Grigoriadis D.E., Haddach M., Ling N., Saunders J. Curr. Med. Chem. 1:2001;63 (e) Gilligan P.J., Robertson D.W., Zaczek R. J. Med. Chem. 43:2000;1641.
6. Zobel A.W., Nickel T., Kunzel H.F., Ackl N., Sonntag A., Ising M., Holsboer F. J. Psych. Res. 34:2000;171.
7. Webster E.L., Lewis D.B., Torpy D.J., Zachman E.K., Rice K.C., Chrousos G.P. Endocrinology. 137:1996;5747.
8. He L., Gilligan P.J., Zaczek R., Fitzgerald L.W., Mc Elroy J., Shen H.S.L., Saye J.A., Kalin N.H., Shelton S., Christ D., Traimor G., Hartig P. J. Med. Chem. 43:2000;449.
9. Gully D., Geslin M., Serva L., Fontaine E., Roger P., Lair C., Dane V., Marcy C., Rouby P.E., Simiand J., Guitard J., Gout G., Steinberg R., Rodier D., Griebel G., Soubrie P., Pascal M., Pruss R., Scatton B., Maffrand J.P., Le Fur G. J. Pharmacol. Exp. Ther. 301:2002;322 Griebel G., Simiand J., Steinberg R., Jung M., Gully D., Roger P., Geslin M., Scatton B., Maffrand J.P., Soubrie P. J. Pharmacol. Exp. Ther. 301:2002;333.
10. Gully D., Geslin M., Serva L., Fontaine E., Roger P., Lair C., Dane V., Marcy C., Rouby P.E., Simiand J., Guitard J., Gout G., Steinberg R., Rodier D., Griebel G., Soubrie P., Pascal M., Pruss R., Scatton B., Maffrand J.P., Le Fur G. J. Pharmacol. Exp. Ther. 301:2002;322 Griebel G., Simiand J., Steinberg R., Jung M., Gully D., Roger P., Geslin M., Scatton B., Maffrand J.P., Soubrie P. J. Pharmacol. Exp. Ther. 301:2002;333.
11. Yuan J., Gulianello M., De Lombaert S., Brodbeck R., Kieltyka A., Hodgetts K.J. Bioorg. Med. Chem. Lett. 12:2002;2133.
12. Grigoriadis D.E., De Souza E.B. Methods Neurosci. 5:1991;510.
13. Chaki S., Okuyama S., Nakazato A., Kumagai T., Okubo T., Ikeda Y., Oshida Y., Hamajima Y., Tomisawa K. Eur. J. Pharmacol. 371:1999;205.
14. Wermuth E. G. In The Practice of Medicinal Chemistry. Wermuth, E. G., Ed. Academic Press: New York, 1996; chapter 35, pp 755-776.
15. Atkinson F., Cole S., Green C., van de Waterbeemd H. Curr. Med. Chem-CNS Agents. 2:2002;229.
16. http://www.neurogen.com/technology.htm.